Literature DB >> 19821135

Intervention study shows outpatient cardiac rehabilitation to be economically at least as attractive as inpatient rehabilitation.

Bernd Schweikert1, Harry Hahmann, Jürgen M Steinacker, Armin Imhof, Rainer Muche, Wolfgang Koenig, Yufei Liu, Reiner Leidl.   

Abstract

BACKGROUND: Since the late 1990 s, cost pressure has led to a growing interest in outpatient rehabilitation in Germany where predominantly inpatient rehabilitation has been provided. Taking into account the feasibility of a randomized design, the aim of this study was to compare outpatient and inpatient cardiac rehabilitation from a societal perspective.
METHOD: A comprehensive cohort design was applied. Costs during rehabilitation were measured using individual documentation of the rehabilitation centers. Economic end points were quality of life (EQ-5D), and total direct and indirect costs. A propensity score approach, integrated into a simultaneous regression framework for cost and effects, was used to control for selection bias. Bootstrap analysis was applied for assessing uncertainty in cost-effectiveness.
RESULTS: A total of 163 patients were included in the study (112 inpatients, 51 outpatients). As randomization was chosen by only 2.5% of participants, the study had to be analyzed as an observational study. Direct costs during inpatient rehabilitation were significantly higher by 600 euro (+/-318; p < 0.001) compared to outpatient rehabilitation (2,016 euro +/- 354 euro vs. 1,416 euro +/- 315), while there was no significant difference in health-related quality of life. Over the 12-month follow-up period, adjusted costs difference in total cost was estimated at -2,895 euro (p = 0.102) and adjusted difference in effects at 0.018 quality-adjusted life years (QALYs) (n.s.) in favor of outpatient treatment.
CONCLUSION: The ratio of mean cost over mean effect difference (incremental cost-effectiveness ratio) indicates dominance of outpatient rehabilitation, but at a considerable statistical uncertainty. However, outpatient rehabilitation cannot be rejected from an economic perspective.

Entities:  

Mesh:

Year:  2009        PMID: 19821135     DOI: 10.1007/s00392-009-0081-6

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN: 1861-0684            Impact factor:   5.460


  23 in total

1.  Use of an angular transformation for ratio estimation in cost-effectiveness analysis.

Authors:  J R Cook; J F Heyse
Journal:  Stat Med       Date:  2000-11-15       Impact factor: 2.373

Review 2.  Exercise-based rehabilitation for patients with coronary heart disease: systematic review and meta-analysis of randomized controlled trials.

Authors:  Rod S Taylor; Allan Brown; Shah Ebrahim; Judith Jolliffe; Hussein Noorani; Karen Rees; Becky Skidmore; James A Stone; David R Thompson; Neil Oldridge
Journal:  Am J Med       Date:  2004-05-15       Impact factor: 4.965

3.  A single European currency for EQ-5D health states. Results from a six-country study.

Authors:  Wolfgang Greiner; Tom Weijnen; Martin Nieuwenhuizen; Siem Oppe; Xavier Badia; Jan Busschbach; Martin Buxton; Paul Dolan; Paul Kind; Paul Krabbe; Arto Ohinmaa; David Parkin; Montserat Roset; Harri Sintonen; Aki Tsuchiya; Frank de Charro
Journal:  Eur J Health Econ       Date:  2003-09

4.  Regression methods for cost-effectiveness analysis with censored data.

Authors:  Andrew R Willan; D Y Lin; Andrea Manca
Journal:  Stat Med       Date:  2005-01-15       Impact factor: 2.373

5.  [Empirical standard costs for health economic evaluation in Germany -- a proposal by the working group methods in health economic evaluation].

Authors:  C Krauth; F Hessel; T Hansmeier; J Wasem; R Seitz; B Schweikert
Journal:  Gesundheitswesen       Date:  2005-10

6.  Effects of cardiac rehabilitation program on exercise capacity and chronotropic variables in patients with orthotopic heart transplant.

Authors:  Hale Karapolat; Sibel Eyigor; Mehdi Zoghi; Tahir Yagdi; Sanem Nalbantgil; Berrin Durmaz; Mustafa Ozbaran
Journal:  Clin Res Cardiol       Date:  2008-03-03       Impact factor: 5.460

7.  Validation of the EuroQol questionnaire in cardiac rehabilitation.

Authors:  B Schweikert; H Hahmann; R Leidl
Journal:  Heart       Date:  2005-03-29       Impact factor: 5.994

8.  Long-term results of a three-week intensive cardiac out-patient rehabilitation program in motivated patients with low social status.

Authors:  B Bjarnason-Wehrens; D Bott; L Benesch; K O Bischoff; B Buran-Kilian; D Gysan; U Hollenstein; W Mayer-Berger; R Wilkniss; G Sauer
Journal:  Clin Res Cardiol       Date:  2006-12-14       Impact factor: 5.460

9.  Productivity loss as a major component of disease-related costs in patients with hypercholesterolemia in Germany.

Authors:  Jacqueline Müller-Nordhorn; Heike Englert; Karl Wegscheider; Hendrike Berger; Frank Sonntag; Heinz Völler; Wolfgang Meyer-Sabellek; Thomas Reinhold; Eberhard Windler; Hugo A Katus; Stefan N Willich
Journal:  Clin Res Cardiol       Date:  2007-12-01       Impact factor: 5.460

10.  Benefit of outpatient cardiac rehabilitation in under-represented patient subgroups.

Authors:  Raban V Jeger; Lucas Jörg; Peter Rickenbacher; Matthias E Pfisterer; Andreas Hoffmann
Journal:  J Rehabil Med       Date:  2007-04       Impact factor: 2.912

View more
  13 in total

1.  Wild type TDP-43 induces neuro-inflammation and alters APP metabolism in lentiviral gene transfer models.

Authors:  Alexander M Herman; Preeti J Khandelwal; G William Rebeck; Charbel E-H Moussa
Journal:  Exp Neurol       Date:  2012-02-28       Impact factor: 5.330

2.  Cost-effectiveness of paclitaxel-coated balloon angioplasty and paclitaxel-eluting stent implantation for treatment of coronary in-stent restenosis in patients with stable coronary artery disease.

Authors:  Klaus Bonaventura; Alexander W Leber; Christian Sohns; Mattias Roser; Leif-Hendrik Boldt; Franz X Kleber; Wilhelm Haverkamp; Marc Dorenkamp
Journal:  Clin Res Cardiol       Date:  2012-02-21       Impact factor: 5.460

3.  Economic implications of intra-aortic balloon support for myocardial infarction with cardiogenic shock: an analysis from the IABP-SHOCK II-trial.

Authors:  Andreas Schuster; Maggie Faulkner; Uwe Zeymer; Taoufik Ouarrak; Ingo Eitel; Steffen Desch; Gerd Hasenfuß; Holger Thiele
Journal:  Clin Res Cardiol       Date:  2015-01-31       Impact factor: 5.460

Review 4.  Medical day hospital care for older people versus alternative forms of care.

Authors:  Lesley Brown; Anne Forster; John Young; Tom Crocker; Alex Benham; Peter Langhorne
Journal:  Cochrane Database Syst Rev       Date:  2015-06-23

5.  Drivers of Payment Variation in 90-Day Coronary Artery Bypass Grafting Episodes.

Authors:  Vinay Guduguntla; John D Syrjamaki; Chad Ellimoottil; David C Miller; Richard L Prager; Edward C Norton; Patricia Theurer; Donald S Likosky; James M Dupree
Journal:  JAMA Surg       Date:  2018-01-01       Impact factor: 14.766

Review 6.  A systematic review of economic evaluations of cardiac rehabilitation.

Authors:  Wai Pong Wong; Jun Feng; Keng Ho Pwee; Jeremy Lim
Journal:  BMC Health Serv Res       Date:  2012-08-08       Impact factor: 2.655

7.  Costs of treating cardiovascular events in Germany: a systematic literature review.

Authors:  Tamara Schmid
Journal:  Health Econ Rev       Date:  2015-09-23

8.  Multivariate Meta-Analysis of Preference-Based Quality of Life Values in Coronary Heart Disease.

Authors:  Jelena Stevanović; Petros Pechlivanoglou; Marthe A Kampinga; Paul F M Krabbe; Maarten J Postma
Journal:  PLoS One       Date:  2016-03-24       Impact factor: 3.240

9.  What patients really think about asthma guidelines: barriers to guideline implementation from the patients' perspective.

Authors:  H Lingner; B Burger; P Kardos; C P Criée; H Worth; E Hummers-Pradier
Journal:  BMC Pulm Med       Date:  2017-01-11       Impact factor: 3.317

10.  Assessing quality of life in a clinical study on heart rehabilitation patients: how well do value sets based on given or experienced health states reflect patients' valuations?

Authors:  Reiner Leidl; Bernd Schweikert; Harry Hahmann; Juergen M Steinacker; Peter Reitmeir
Journal:  Health Qual Life Outcomes       Date:  2016-03-22       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.